Eight years of experience with biological treatment in juvenile idiopathic arthritis

Mourão, Ana Filipa; Rodrigues, Ana Maria; Vinagre, Filipe; Sousa, E; Polido-Pereira, Joaquim; Macieira, Carla; Ramos, Filipa; Costa, Jerome; Pedro, J. Branco; Silva, J Pereira da; Fonseca, JE; Santos, María José

doi:10.1186/1479-5876-8-s1-p64

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biological treatment found to be safe and effective in severe JIA or refractory cases to synthetic DMARDs (33) , in our cohort biological agents were used in 105/210 (50%), and they include Anti-TNF (Tumor necrosis factor) which is a cytokine play role in the pathogenesis of JIA and found in increased levels in the synovial uid. Tocilizumab a monoclonal antibody directed against IL-6 receptor; increased serum levels found in systemic arthritis, Anakinra is a human recombinant IL-1 receptor antagonist and play a role in the pathogenesis of JIA and is a preferred treatment of systemic arthritis, Rituximab is a human monoclonal antibody directed against CD20 lymphocytes leading to increase B-cell apoptosis and decrease mature B cell expressing CD20 (34) , anti-TNF drugs were used in our cohort in 74/210 (35.2%) in which in iximab was the commonest anti-TNF used 30/210 (14.2%), followed by Etanercept 25/210 (12%) while Adalimumab was used in 15/210 (7.1%) and Golimumab in four patients (1.9%).…”

Section: Discussionmentioning

confidence: 96%

Juvenile Idiopathic Arthritis in Jordan: Single-Center Experience

Alzyoud¹,

Alsuweiti²,

Almaaitah³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Juvenile idiopathic arthritis (JIA) is a heterogeneous group of disorders, including all forms of arthritis, begin in children who are less than 16 years old. This study aims to evaluate the clinical and laboratory features of JIA in Jordanian children in a single center.Methods: A retrospective analysis of the medical records of pediatric patients who were diagnosed as JIA based on the International League of Associations for Rheumatology (ILAR) criteria from 2015 through 2019 at a pediatric Rheumatology clinic in Queen Rania Children Hospital. All patients were below the age of 14 at the time of diagnosis. Collected data included age, gender, age at initial presentation and diagnosis, JIA subtypes, and laboratory data.Results: A total of 210 patients were included in this cohort (94 males and 116 females) with a mean age at diagnosis 5.33 ± 3.4 years and the mean age at onset of the disease was 5.08 ± 3.4 years (range 7 months – 14 years). Oligoarticular JIA was the commonest subtype (54.7%), followed by systemic arthritis (17.1%), polyarticular (12.3%). ANA was positive in 70 patients (33.6%). Uveitis occurred in thirty (14.2%) patientsConclusion: To the best of our knowledge, this cohort is the first report on JIA in Jordan, in comparison with other regional and international published reports, Oligoarticular JIA found to be the most common Subtype in our experience. To have more details about JIA characteristics, a population-based rather than a single-center study needs to be conducted in Jordan

show abstract

Section: Discussionmentioning

confidence: 96%

Juvenile Idiopathic Arthritis in Jordan: Single-Center Experience

Alzyoud¹,

Alsuweiti²,

Almaaitah³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Biological treatment has been found to be safe and effective in severe JIA or refractory cases to synthetic DMARDs (33) . In our cohort, biological agents were used in 105 (50%) patients.…”

Section: Discussionmentioning

confidence: 99%

Juvenile idiopathic arthritis in Jordan: Single center experience

Alzyoud¹,

Alsuweiti²,

Almaaitah³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Juvenile idiopathic arthritis (JIA) is a heterogeneous group of disorders, including all forms of arthritis, which develops in children who are less than 16 years old. This study aimed to evaluate the clinical and laboratory features of JIA in a single center in Jordan.Methods: A retrospective analysis of the electronic medical records of pediatric patients diagnosed with JIA based on the International League of Associations for Rheumatology (ILAR) criteria during the period from 2015 to 2019 at the Pediatric Rheumatology Clinic in the Queen Rania Children’s Hospital. All patients were below the age of 14 years at the time of diagnosis and followed for at least six months. Collected data consisted of age, gender, age at initial presentation and diagnosis, JIA subtype, laboratory data, treatment options, and outcome.Results: A total of 210 patients were included in this cohort (94 males and 116 females) with the mean age at diagnosis and mean age at onset of 5.33 ± 3.40 years and 5.08 ± 3.40 years (range: 7 months – 14 years), respectively. Oligoarticular JIA was the commonest subtype (54.7%), followed by systemic arthritis (17.1%) and polyarticular arthritis (12.3%). ANA was positive in 70 patients (33.6%). Uveitis occurred in thirty (14.2%) patients.Conclusion: To the best of our knowledge, this study on this cohort is the first report on JIA in Jordan, in comparison with other regionally and internationally published reports. Oligoarticular JIA was found to be the most common subtype. For detailed knowledge on JIA characteristics and patterns, a population-based, rather than a single center study, should be conducted in Jordan.

show abstract

“…Biological treatment has been found to be safe and effective in severe JIA or refractory cases to synthetic DMARDs [ 35 ]. In our cohort, biological agents were used in 105 (50%) patients.…”

Section: Discussionmentioning

confidence: 99%

Juvenile idiopathic arthritis in Jordan: single center experience

et al. 2021

View full text Add to dashboard Cite

Background Juvenile idiopathic arthritis (JIA) is a heterogeneous group of disorders, including all forms of arthritis, which develops in children who are less than 16 years old. This study aimed to evaluate the clinical and laboratory features of JIA in a single center in Jordan. Methods A retrospective analysis of the electronic medical records of Pediatric patients diagnosed with JIA based on the International League of Associations for Rheumatology (ILAR) criteria during the period from 2015 to 2019 at the Pediatric Rheumatology Clinic in the Queen Rania Children’s Hospital. All patients were below the age of 14 years at the time of diagnosis and followed for at least 6 months. Collected data consisted of age, gender, age at initial presentation and diagnosis, JIA subtype, laboratory data, treatment options, and outcome. Results A total of 210 patients were included in this cohort (94 males and 116 females) with the mean age at diagnosis and mean age at onset of 5.33 ± 3.40 years and 5.08 ± 3.40 years (range: 7 months – 14 years), respectively. Oligoarticular JIA was the commonest subtype (54.7%), followed by systemic arthritis (17.1%) and polyarticular arthritis (12.3%). ANA was positive in 70 patients (33.6%). Uveitis occurred in 30 (14.2%) patients. Conclusion To the best of our knowledge, this study on this cohort is the first report on JIA in Jordan, in comparison with other regionally and internationally published reports. Oligoarticular JIA was found to be the most common subtype. For detailed knowledge on JIA characteristics and patterns, a population-based, rather than a single center study, should be conducted in Jordan.

show abstract

Eight years of experience with biological treatment in juvenile idiopathic arthritis

Cited by 3 publications

References 0 publications

Juvenile Idiopathic Arthritis in Jordan: Single-Center Experience

Juvenile Idiopathic Arthritis in Jordan: Single-Center Experience

Juvenile idiopathic arthritis in Jordan: Single center experience

Juvenile idiopathic arthritis in Jordan: single center experience

Contact Info

Product

Resources

About